Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03760003 · ClinicalTrials.gov registry record · Phase 2
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
A Phase 2 study, sponsored by Abivax S.A..
- Completed
- Registry status
- Phase 2
- Development phase
- 355
- Enrollment target
NCT03760003 is a Phase 2 study that has completed, run by Abivax S.A.. The registered enrollment target is 355 participants.
The verdict
NCT03760003, a Phase 2 study, has completed, sponsored by Abivax S.A..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 355 participants
- Enrollment target
Study Summary
Phase 2b study to evaluate the efficacy and the safety of 3 dose-levels of ABX464, administered daily in patients with moderate to severe Ulcerative Colitis.
Interventions
- DRUG Placebo
- DRUG ABX464 100 mg
- DRUG ABX464 50 mg
- DRUG ABX464 25 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 355 participants |
| Start Date | 2019-08-13 |
| Est. Completion | 2021-04-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03760003
The ClinicalTrials.gov registry entry for NCT03760003 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 355 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abivax S.A., which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT03760003 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03760003 about?
NCT03760003 is a clinical study titled "Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis". Phase 2b study to evaluate the efficacy and the safety of 3 dose-levels of ABX464, administered daily in patients with moderate to severe Ulcerative Colitis.
What is the current status of trial NCT03760003?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 355 participants. The study started on 2019-08-13. Estimated completion is 2021-04-16.
What interventions are being tested in trial NCT03760003?
The interventions under investigation include: Placebo (DRUG), ABX464 100 mg (DRUG), ABX464 50 mg (DRUG), ABX464 25 mg (DRUG).
Who is sponsoring clinical trial NCT03760003?
This trial is sponsored by Abivax S.A., which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.